Aurobindo Pharma Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 31.9% YoY, showing strong momentum
- Operating margins have improved to 27.4% from 23.0%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.04x)
- Company comfortably covers its interest (15.8x coverage)
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- Company has a low return on capital employed of 11.8%
- Company has a low return on equity of 10.0% over last 3 years
- Company's sales have been declining over the last five years
- Company has delivered a poor profit growth of -5.0% over past five years
- Though reporting repeated profits, the company pays out little dividend (9.6%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BIOCON | 390.95 | 128.63 | 63712.89 | 0.13 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,364 | 2,648 | 2,664 | 2,866 | 2,425 | 2,758 | 2,884 | 2,721 | 2,822 | 2,760 | 2,726 | 2,747 | 2,800 | |
| 1,968 | 2,124 | 2,210 | 2,119 | 1,961 | 2,104 | 2,203 | 2,135 | 2,052 | 2,065 | 1,958 | 2,005 | 2,033 | |
| Operating Profit | 395 | 525 | 453 | 747 | 464 | 654 | 680 | 586 | 770 | 695 | 769 | 742 | 766 |
| OPM % | 16.71% | 19.82% | 17.02% | 26.07% | 19.13% | 23.72% | 23.58% | 21.53% | 27.30% | 25.18% | 28.19% | 27.01% | 27.37% |
| 95 | 67 | 331 | 123 | 65 | 123 | 54 | 114 | 84 | 160 | 113 | 214 | 242 | |
| Interest | 32 | 37 | 61 | 53 | 51 | 52 | 66 | 61 | 60 | 57 | 48 | 47 | 47 |
| Depreciation | 60 | 66 | 64 | 65 | 67 | 68 | 68 | 94 | 70 | 71 | 72 | 72 | 69 |
| Profit before Tax | 426 | 510 | 687 | 780 | 446 | 724 | 633 | 556 | 750 | 755 | 782 | 876 | 1,008 |
| Tax % | 25.35% | 25.53% | 9.23% | 25.80% | 26.26% | 25.73% | 25.42% | 26.52% | 25.46% | 23.03% | 25.56% | 21.01% | 26.87% |
| Net Profit | 318 | 380 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 | 582 | 692 | 737 |
| 5.43 | 6.48 | 10.65 | 9.88 | 5.62 | 9.21 | 8.13 | 7.03 | 9.63 | 10.01 | 10.02 | 11.92 | 12.75 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,607 | 10,270 | 12,258 | 13,371 | 15,824 | 11,287 | 8,457 | 10,646 | 10,933 | 11,172 | 11,033 | |
| 7,233 | 7,600 | 9,849 | 10,673 | 11,704 | 9,832 | 6,952 | 8,422 | 8,376 | 8,096 | 8,061 | |
| Operating Profit | 2,374 | 2,670 | 2,409 | 2,698 | 4,120 | 1,456 | 1,505 | 2,224 | 2,558 | 3,075 | 2,971 |
| OPM % | 24.71% | 26.00% | 19.66% | 20.18% | 26.04% | 12.90% | 17.79% | 20.89% | 23.39% | 27.53% | 26.93% |
| 136 | 81 | 199 | 389 | 590 | 614 | 444 | 616 | 328 | 587 | 728 | |
| Interest | 45 | 53 | 231 | 243 | 29 | 17 | 75 | 183 | 230 | 213 | 200 |
| Depreciation | 286 | 355 | 413 | 473 | 488 | 415 | 243 | 255 | 297 | 285 | 284 |
| Profit before Tax | 2,179 | 2,343 | 1,965 | 2,370 | 4,193 | 1,637 | 1,631 | 2,403 | 2,358 | 3,164 | 3,422 |
| Tax % | 21.66% | 22.63% | 22.14% | 20.81% | 25.76% | 11.16% | 23.84% | 20.93% | 25.93% | 23.67% | 24.22% |
| Net Profit | 1,707 | 1,813 | 1,530 | 1,877 | 3,113 | 1,455 | 1,242 | 1,900 | 1,747 | 2,415 | 2,593 |
| EPS | 29.16 | 30.94 | 26.11 | 32.03 | 53.13 | 24.83 | 20.94 | 32.43 | 30.08 | 41.58 | — |
| Dividend Payout % | 8.58% | 8.08% | 9.58% | 9.37% | 7.53% | 36.25% | 14.15% | 13.88% | 0.00% | 9.62% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 2%
- 5 Years:
- -7%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 4%
- 5 Years:
- -5%
- 3 Years:
- 25%
STOCK PRICE CAGR
- 10 Years:
- 8%
- 5 Years:
- 18%
- 3 Years:
- 24%
- 1 Year:
- 51%
RETURN ON EQUITY
- 10 Years:
- 14%
- 5 Years:
- 9%
- 3 Years:
- 10%
- Last Year:
- 11%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
| 8,378 | 9,924 | 11,292 | 12,994 | 15,866 | 17,059 | 17,975 | 19,664 | 20,476 | 22,660 | |
| 3,054 | 3,719 | 4,520 | 3,741 | 4,028 | 1,879 | 4,185 | 2,839 | 3,859 | 3,688 | |
| Trade Payables | 1,218 | 1,629 | 1,841 | 1,924 | 2,061 | 1,661 | 2,202 | 1,789 | 1,787 | 1,832 |
| 315 | 463 | 429 | 846 | 2,080 | 5,207 | 3,744 | 4,518 | 5,714 | 6,179 | |
| Total Liabilities | 13,023 | 15,794 | 18,141 | 19,564 | 24,093 | 25,865 | 28,166 | 28,869 | 31,894 | 34,417 |
| 3,212 | 3,393 | 4,150 | 4,418 | 4,472 | 3,586 | 3,688 | 2,419 | 2,337 | 2,544 | |
| Capital Work in Progress | 878 | 1,100 | 750 | 815 | 719 | 225 | 239 | 133 | 88 | 229 |
| 1,682 | 1,968 | 2,339 | 2,527 | 5,010 | 6,584 | 8,105 | 13,393 | 15,210 | 17,562 | |
| 2,434 | 3,409 | 3,971 | 4,360 | 4,841 | 3,356 | 4,125 | 2,368 | 2,359 | 2,361 | |
| 22 | 19 | 25 | 44 | 33 | 17 | 21 | 3,777 | 4,195 | 4,210 | |
| Cash & Bank | 34 | 246 | 76 | 86 | 386 | 51 | 373 | 94 | 298 | 162 |
| 4,761 | 5,659 | 6,830 | 7,314 | 8,632 | 12,046 | 11,614 | 6,686 | 7,407 | 7,350 | |
| Total Assets | 13,023 | 15,794 | 18,141 | 19,564 | 24,093 | 25,865 | 28,166 | 28,869 | 31,894 | 34,417 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,939 | 1,452 | 1,012 | 2,580 | 3,621 | 4,419 | 2,117 | 1,715 | 1,646 | 2,933 | |
| Cash from Investing | -1,542 | -991 | -1,297 | -952 | -2,649 | -1,614 | -3,458 | -160 | -2,066 | -2,025 |
| Cash from Financing | -1,329 | 440 | 599 | -1,255 | -28 | -2,448 | 1,719 | -1,837 | 616 | -1,072 |
| -414 | 371 | -168 | -5 | 318 | -334 | 78 | -282 | 196 | -164 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-12 - Aurobindo Pharma Limited has informed the Exchange about Acquisition
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
2026-09-03 - Aurobindo Pharma Limited has submitted copy of Newspaper Publications.
2026-09-01 - AUROPHARMA: Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned subsidiary by the name of Avogent Lifesciences Private Limited in India by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
News
Recent coverage and analyst commentary for AUROPHARMA
Loading news…
AI Stock Analyst
Aurobindo Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account